Overview of omega-3 Fatty Acid therapies.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic methodology.
What was done
This paper provides a narrative formulary review comparing dietary supplements and prescription omega-3 fatty acid formulations, specifically mixed EPA/DHA ethyl esters versus purified icosapent ethyl (EPA only), for managing hypertriglyceridemia in statin-treated and non-statin-treated patients.
What was found
The abstract reports no numerical data. It describes that both mixed EPA/DHA formulations and purified icosapent ethyl lower triglyceride levels and other atherogenic markers. However, mixed EPA/DHA formulations can increase low-density lipoprotein cholesterol (LDL-C), whereas icosapent ethyl does not raise LDL-C levels. Prior outcomes trials combining omega-3 fatty acids with statins failed to show additional cardiovascular event reductions, prompting the REDUCE-IT cardiovascular outcomes trial.
Why it matters
It highlights a clinically relevant pharmacological distinction between omega-3 formulations: pure EPA agents reduce triglycerides without raising LDL-C, the primary lipid target in dyslipidemia management.
Limits
The abstract describes a narrative overview with no original human data, systematic search protocol, or statistical synthesis. No quantitative effect sizes, sample sizes, or trial characteristics are provided.
Cited by
- supports Lovaza is an ethyl ester mixture of EPA and DHA, while Vascepa is an EPA-only ethyl ester formulation.